Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor formulated as being a cure for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and security to handle regulatory requirements. Inhibition of galectin-3 with GB1211 wasn't connected to any treatment- or dose-associated trends https://robertk665wis8.wikiconverse.com/user